First Human Trials for Recombinant Dengue Fever Vaccine
Phase one clinical trials to start for Dengue Fever Vaccine program
Acuvax Limited announces that the dengue fever vaccine is set to begin Phase 1 safety trials in the USA through its affiliate company Hawaii Biotech Inc. Hawaii Biotech Inc, has initiated this phase one clinical study with their monovalent dengue vaccine candidate. The double-blind, placebo controlled, dose escalation safety study in healthy subjects is being conducted at the St. Louis University Centre for Vaccine Development in the United States. Vaccine recipients in this study will also be monitored for virus neutralizing antibodies.
Acuvax CEO and Hawaii Biotech Inc Director, Dr William Ardrey said: “We are pleased to deliver on our guidance to the market that the recombinant vaccine will be trialled in humans in the USA this quarter.”
According to the company, Hawaii Biotech’s Dengue monovalent vaccine candidate is the first recombinant subunit vaccine for dengue to enter clinical studies. Hawaii Biotech intends to test a dengue tetravalent vaccine candidate, developed using the company’s recombinant subunit vaccine technology, within a year. Hawaii Biotech’s dengue subunit vaccine candidate has been developed with financial assistance from the National Institutes of Health, the Department of Defence, and the Paediatric Dengue Vaccine Initiative (which is funded by the Bill & Melinda Gates Foundation).
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous